Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy,Journal of Hematology & Oncology

当前位置： X-MOL 学术 › J. Hematol. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
Journal of Hematology & Oncology ( IF 28.5 ) Pub Date : 2023-09-29 , DOI: 10.1186/s13045-023-01503-8
Letong Cai ₁ , Yuchen Li ₁ , Jiaxiong Tan ₁ , Ling Xu _{1,

2} , Yangqiu Li _{1,

2}

Affiliation

Correction to: Cai et al. Journal of Hematology & Oncology (2023) 16:101 https://doi.org/10.1186/s13045-023-01499-1

The original article [1] contained an error mistakenly introduced by the production team whereby co-first authorship for the first three co-authors was omitted. This has since been restored accordingly.

Cai L, Li Y, Tan J, et al. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16:101. https://doi.org/10.1186/s13045-023-01499-1.
Article CAS PubMed PubMed Central Google Scholar

Download references

Author notes

Letong Cai, Yuchen Li and Jiaxiong Tan contributed equally to this work.

Authors and Affiliations

Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, 510632, China
Letong Cai, Yuchen Li, Jiaxiong Tan, Ling Xu & Yangqiu Li
Key Laboratory of Viral Pathogenesis & Infection Prevention and Control (Jinan University), Ministry of Education, Guangzhou, 510632, China
Ling Xu & Yangqiu Li

Authors

Letong CaiView author publications
You can also search for this author in PubMed Google Scholar
Yuchen LiView author publications
You can also search for this author in PubMed Google Scholar
Jiaxiong TanView author publications
You can also search for this author in PubMed Google Scholar
Ling XuView author publications
You can also search for this author in PubMed Google Scholar
Yangqiu LiView author publications
You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Ling Xu or Yangqiu Li.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

Cite this article

Cai, L., Li, Y., Tan, J. et al. Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol 16, 105 (2023). https://doi.org/10.1186/s13045-023-01503-8

Download citation

Published: 29 September 2023
DOI: https://doi.org/10.1186/s13045-023-01503-8

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

中文翻译：

更正：针对癌症免疫治疗的 LAG-3、TIM-3 和 TIGIT

更正：蔡等人。血液学与肿瘤学杂志 (2023) 16:101 https://doi.org/10.1186/s13045-023-01499-1

原文章[1]包含制作团队错误引入的错误，省略了前三位共同作者的共同第一作者身份。此后已相应恢复。

蔡L，李Y，谭J，等。针对癌症免疫治疗的 LAG-3、TIM-3 和 TIGIT。J Hematol Oncol。2023；16：101。https://doi.org/10.1186/s13045-023-01499-1。
文章 CAS PubMed PubMed Central Google Scholar

下载参考资料

作者笔记

蔡乐童、李雨辰和谭家雄对这项工作做出了同等贡献。

作者和单位

暨南大学医学院血液研究所再生医学教育部重点实验室, 广州 510632
蔡乐童、李雨辰、谭家雄、徐凌、李阳秋
病毒发病机制与感染防控教育部重点实验室(暨南大学),广州 510632
徐凌&李阳秋

作者

蔡乐童查看作者出版物
您也可以在PubMed Google Scholar中搜索该作者
李雨辰查看作者出版物
您也可以在PubMed Google Scholar中搜索该作者
谭家雄查看作者出版物
您也可以在PubMed Google Scholar中搜索该作者
徐凌查看作者出版物
您也可以在PubMed Google Scholar中搜索该作者
李阳秋查看作者出版物
您也可以在PubMed Google Scholar中搜索该作者

通讯作者

通讯作者：Ling Xu 或 Yangqi Li。

出版商备注

施普林格·自然对于已出版的地图和机构隶属关系中的管辖权主张保持中立。

开放获取本文根据知识共享署名 4.0 国际许可证获得许可，该许可证允许以任何媒介或格式使用、共享、改编、分发和复制，只要您对原作者和来源给予适当的认可，提供知识共享许可的链接，并指出是否进行了更改。本文中的图像或其他第三方材料包含在文章的知识共享许可中，除非材料的出处中另有说明。如果文章的知识共享许可中未包含材料，并且您的预期用途不受法律法规允许或超出了允许的用途，则您需要直接获得版权所有者的许可。要查看此许可证的副本，请访问 http://creativecommons.org/licenses/by/4.0/。知识共享公共领域奉献豁免 (http://creativecommons.org/publicdomain/zero/1.0/) 适用于本文中提供的数据，除非数据的信用额度中另有说明。

转载和许可